NCT03308474

Myeloma Registry Platform (MYRIAM)

Clinical Research Platform for Molecular Testing, Treatment and Outcome of Patients With Multiple Myeloma (Myeloma Registry Platform; MYRIAM)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 2,200 (estimated)
• Sponsor: iOMEDICO AG · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Multiple Myeloma in Germany.

Detailed description

MYRIAM is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of multiple myeloma in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Health-realted quality of life in patients with multiple myeloma (MyLife) will be evaluated for up to five years.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
OTHER	Routine care as per site standard.	Physician's choice according to patient's needs.

Timeline

• Start date: 2017-09-25
• Primary completion: 2026-12-01
• Completion: 2028-12-01
• First posted: 2017-10-12
• Last updated: 2026-01-27

Locations

1 site across 1 country: Germany